Efficient Operations

Higher production rates are possible with Mannogem Mannitol direct compression grades because tablet robustness is not compromised with increased press speeds. Mannogem has low sensitivity to press speed and can be tableted over a wide range of dwell times. Its compaction mechanism, based on the increased surface area resulting from brittle fracture deformation, reduces sensitivity to lubricant levels and extended blending times. The high binding capacity of Mannogem makes it an excellent tablet binder, capable of producing quality, robust tablets at lower compression forces. These attributes yield low friability that can withstand the stresses associated with film coating, printing and packaging.

Improved Formulations, Better Tablets

Mannitol dissolves rapidly while retaining porosity, making it the excipient of choice in lyophilized and directly compressible orodispersible formulations. More of the API can be available because it does not become entrained with insoluble binders. This can allow less API to be used, leading to fewer side effects for the patient and reduced cost for the manufacturer.

Excellent Mouthfeel

Mannitol has a negative heat of solution which imparts a cooling sensation. It dissolves quickly, delivering excellent palatability through a creamy texture and a mild sweetness.

Improved Patient Experience

Mannogem Mannitol helps improve the palatability of tablet formulations, and can enable formulators to create dosage forms which are easier to take, and more portable. Mannogem can help drive compliance, particularly with sensitive populations such as children and the elderly.

Increased Productivity

Your team works hard to create a product that patients want to take. Selecting an excipient that makes their job easier and the patient experience better can be a challenge. Improve the patient experience and benefit from efficient manufacturing operations by formulating with Mannogem Mannitol.

Compliance

Mannogem Mannitol helps improve the palatability of tablet formulations, and can enable formulators to create dosage forms which are easier to take, and more portable. Mannogem can help drive compliance, particularly with sensitive populations such as children and the elderly.

Innovation

These characteristics make Mannogem Mannitol an ideal excipient for the formulation of convenient, patient friendly dosage forms that are easy to administer. It can be used to create alternate dosage forms, such as chewables, and has been used in 505b2 formulations. These grades are easily wettable and dissolve rapidly, leading to increased drug release.
Mannogem XL technology is an innovative way to create mannitol for direct compression. The technology is designed to improve the formulation experience as well as to enhance formulation performance. It creates multifunctional, compendial grades of DC spray dried mannitol that provides superior binding and quick disintegration, resulting in superior tabletability.

XL provides greater manufacturing consistencies through its performance and its tight particle size range. Using XL, it is possible to increase patient compliance through tablet size reduction and faster disintegration times.

Products created with Mannogem XL technology retain the positive qualities of compendial mannitol while boasting enhancements over standard competitive mannitol:

- **25% Higher Tablet Hardness**
- **38% Quicker Disintegration per Tablet**
- **50% Higher Drug Loading Capability**
- **200% Friability Improvement at Low Compression Force**

Mannogem Granular Grades are manufactured through a wet granulation process and have a larger particle size than our Mannogem spray dried material. They exhibit excellent flow, disintegration and compression properties. These products are ideal for formulating tablets with taste masked APIs, which often have a larger particle size due to the taste making process.

Mannogem Granular has a larger particle size that has shown to contribute to a softer texture for chewable tablets. The larger particle size allows it to match specific particle size and density constraints to minimize segregation during transport and manufacturing.

Mannogem 2080 has a smaller average particle size and a tighter overall particle size range. This lower particle size produces higher surface area relative to Mannogem Granular, making it an effective API carrier system.

Mannogem Mannitol Powder is an excellent excipient for use in wet granulation and lyophilization. It dries rapidly, resulting in shorter processing time and increased productivity.

Mannitol is also a good excipient for hot melt extrusion applications. It melts without decomposition at a temperature of approximately 165° C. Its rapid recrystallization upon cooling make it an attractive carrier to improve solubility of poorly soluble APIs.
Application Guide for Operations

Mannogem Mannitol allows for higher production rates, reduced sensitivity to lubricants, low friability, and high binding capacity. Your team will want to work with Mannogem because it makes your operation run more efficiently.

Reference the chart to the right/below to find your process of choice. There, you will be able to see which grade of Mannogem best suits your needs.

Once you have determined the grade that works for you, contact us for a sample. Our technical team is available to answer questions and discuss best practices.

Use-Based Formulation Guide

Development of dose forms that are age-appropriate and acceptable to patients is a clear trend with regulators. The excellent organoleptics of Mannogem, together with its high compatibility and improved tabletability of our XL Grade over standard mannitol, mean that it can be used by formulators in projects to cover a wide range of dose form concepts and dosage strengths.

The chart below illustrates dosage form options and which grade of Mannogem Mannitol works best for the desired product.

Our regionally-based technical experts are available to come and work with your team to optimize the formulation and delivery method of your choice. Contact us to request a sample and get started.

<table>
<thead>
<tr>
<th>Mannogem XL</th>
<th>Mannogem EZ</th>
<th>Mannogem Granular and 2080</th>
<th>Mannogem Powder</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td></td>
</tr>
<tr>
<td>Dry blending of micronized and low dose actives</td>
<td>Dry blending</td>
<td>Direct compression</td>
<td>Swallow tablets</td>
</tr>
<tr>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td></td>
</tr>
<tr>
<td>Dry blending</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>Orally disintegrating tablets</td>
</tr>
<tr>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>Chewable tablets and lozenges</td>
</tr>
<tr>
<td>Direct compression</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>Tablets with taste masked APIs</td>
</tr>
<tr>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>Sachets and stickpacks</td>
</tr>
<tr>
<td>Roller compaction</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>Liquid suspensions/syrups</td>
</tr>
<tr>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>Effervescent tablets</td>
</tr>
<tr>
<td>Wet granulation</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td></td>
</tr>
<tr>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td></td>
</tr>
<tr>
<td>Lyophilization</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td></td>
</tr>
<tr>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td></td>
</tr>
<tr>
<td>Hot melt extrusion</td>
<td>✔️ ✔️</td>
<td>✔️ ✔️</td>
<td></td>
</tr>
</tbody>
</table>
All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limited to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.

SPI PHARMA EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, CURRENCY, COMPLETENESS AND/OR THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INFORMATION CONTAINED IN THIS BROCHURE AND/OR ANY PRODUCT DESCRIBED OR PROMOTED IN THIS BROCHURE, INCLUDING WARRANTIES WITH RESPECT TO INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER RIGHTS OF A THIRD PARTY. We reserve the right to change product specification and not specified properties of the products without prior notice.

Order# SPI-EXC-MCM-0100-09201900
09-2019 | All rights reserved
© 2019 SPI Pharma